Tag: FUSN, Analyst Rating

Brookline Capital Management raises its FY2023 earnings per share estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN).

by Elaine Mendonça

February 20, 2023

Ticker symbol: FPHX, which stands for Fusion Pharmaceuticals INC In a research note that was given out to clients and ...

Brokerages have assigned a consensus rating of “Buy” to Fusion Pharmaceuticals Inc. (NASDAQ:FUSN).

by Roberto Liccardo

January 24, 2023

According to Bloomberg, the seven rating agencies presently keeping an eye on Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) have collectively provided ...

DISCLAIMER

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

Categories

Best Stocks to buy now
Crypto
Dow Jones Today
Pre-IPO and Startups
Tech stocks
Utility Stocks

Data and Tools
Quote
Dow Jones Today

Follow us on Social Media
Facebook – YouTube – Twitter

Write for us
Finance – Business

Best Stocks to Buy Now

We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.

No Result

View All Result